CDNA vs NTRA
CDNA: CareDx is the leading provider of genomics-based molecular diagnostics for transplant patients, combining non-invasive cell-free DNA and gene expression testing with digital health and patient solutions to improve transplant outcomes across heart, kidney, and lung. NTRA: Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant health.
Side-by-side fundamentals
| Metric | CDNA | NTRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $37.78 | $264.22 | |
| Market cap as of 2026-07-23 | $2.0B | $37.9B | |
| PEG as of 2026-07-23 | n/a | -13.63 | |
| Net margin as of 2026-07-23 | -2.0% | -9.1% | CDNA higher |
| Gross margin as of 2026-07-23 | +68.9% | +65.1% | CDNA higher |
| Operating margin as of 2026-07-23 | -3.9% | -13.0% | CDNA higher |
| ROE as of 2026-07-23 | -2.6% | -15.1% | CDNA higher |
| ROA as of 2026-07-23 | -1.9% | -10.5% | CDNA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.05 | CDNA lower |
| Revenue growth (YoY) as of 2026-07-23 | +19.2% | +36.6% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +5.7% | +41.1% | NTRA higher |
| Beta as of 2026-07-23 | 2.46 | 1.54 | |
| 1-year return as of 2026-07-22 close | +190.2% | +88.8% | CDNA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.